Effect of Lactobacillus paracasei CNCM I‐1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. Issue 4 (1st May 2018)

• Record Type: Journal Article
• Authors: Cremon, Cesare; Guglielmetti, Simone; Gargari, Giorgio; Taverniti, Valentina; Castellazzi, Anna Maria; Valsecchi, Chiara; Tagliacarne, Carlotta; Fiore, Walter; Bellini, Massimo; Bertani, Lorenzo; Gambaccini, Dario; Cicala, Michele; Germanà, Bastianello; Vecchi, Maurizio; Pagano, Isabella; Barbaro, Maria Raffaella; Bellacosa, Lara; Stanghellini, Vincenzo; Barbara, Giovanni
• Is Part Of: United European Gastroenterology journal. Volume 6:Issue 4(2018)
• Page Start: 604
• Page End: 613
• Publication Date: 2018-05-01
• Subjects: Irritable bowel syndrome -- dietary compounds -- probiotics -- microbiota; Gastroenterology -- Periodicals; Periodicals; 616.33005
• DOI: 10.1177/2050640617736478
• Languages: English
• ISSNs: 2050-6406

Abstract

Abstract : Background: Evidence suggests a role of intestinal microbiota‐host interactions in the pathophysiology and symptoms of irritable bowel syndrome (IBS). Objective: The objective of this article is to assess the effects of Lactobacillus paracasei CNCM I‐1572 on clinical and gut microbiota‐related factors in IBS. Methods: We conducted a multicenter, randomized, double‐blind, cross‐over, 18‐week, placebo‐controlled, pilot trial assessing the effect of Lactobacillus paracasei CNCM I‐1572 on symptoms, gut microbiota composition, fecal short chain fatty acid (SCFA), immunoglobulin A, and cytokines in IBS. The intestinal microbial ecosystem was characterized by 16S rRNA gene profiling. Results: Forty IBS patients were enrolled from five Italian centers. Lactobacillus paracasei CNCM I‐1572 did not significantly improve IBS symptoms, including primary efficacy variables worst abdominal pain/discomfort and IBS degree of relief. Interestingly, Lactobacillus paracasei CNCM I‐1572 induced a significant reduction in genus Ruminococcus, dominated by taxa related to Ruminococcus bromii and Ruminococcus callidus, a significant increase in the SCFAs acetate and butyrate, and a significant reduction in the pro‐inflammatory cytokine interleukin‐15. Conclusions: This pilot study shows that Lactobacillus paracasei CNCM I‐1572 is able to modulate gut microbiota structure/function and reduce immune activation in IBS. As no statistically significant effect on IBS‐symptoms was found, further studies are necessary to determine the role of this probiotic in IBS. The study was registered at ClinicalTrials.gov registry under identifier NCT02371499.